^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    arcotatug tavatecan (TAK-921)

    i
    Other names: TAK-921, IBI-343, IBI343
    Company:
    Innovent Biologics, Takeda
    Drug class:
    Topoisomerase I inhibitor, CLDN18.2-targeted antibody-drug conjugate
    Related drugs:
    Apply
    IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (NCT07483567)
    Phase 2
    Innovent Biologics (Suzhou) Co. Ltd.
    Not yet recruiting
    Last update posted :
    03/19/2026
    Initiation :
    03/30/2026
    Primary completion :
    06/30/2030
    Completion :
    06/30/2031
    CLDN18
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • oxaliplatin • Teysuno (gimeracil/oteracil/tegafur) • arcotatug tavatecan (TAK-921)
    IBI343 Combined with Chemotherapy in Advanced Pancreatic Cancer (NCT06770439)
    Phase 2
    Zhejiang University
    Not yet recruiting
    Last update posted :
    01/13/2025
    Initiation :
    01/01/2025
    Primary completion :
    01/01/2027
    Completion :
    01/01/2028
    CLDN18
    |
    gemcitabine • albumin-bound paclitaxel • arcotatug tavatecan (TAK-921)
    Study of IBI343 in Subjects With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma (NCT06321913)
    Phase 2
    Harbin Medical University
    Not yet recruiting
    Last update posted :
    03/20/2024
    Initiation :
    03/15/2024
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    CLDN18
    |
    CLDN18.2 expression
    |
    Tyvyt (sintilimab) • arcotatug tavatecan (TAK-921)
    A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (NCT05458219)
    Phase 1
    Innovent Biologics (Suzhou) Co. Ltd.
    Recruiting
    Last update posted :
    11/11/2022
    Initiation :
    10/26/2022
    Primary completion :
    05/31/2024
    Completion :
    10/31/2024
    CLDN18
    |
    arcotatug tavatecan (TAK-921)